Capsadyn

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: Capsadyn
Generic name: CAPSAICIN
Manufacturer: Chorda Pharma, Inc
Product type: HUMAN OTC DRUG
SPL set ID: 07731045-0d2b-76b7-e063-6294a90af921
SPL ID: 07731045-0d2c-76b7-e063-6294a90af921
Version: 1
Effective date: 2023-10-11
Source export date: 2026-09-28
Source partition: 4
Source file: https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-09-28/c7ca0b7091cdaeab3f27713a6eef00adcf8fe722383633ddce61531b4c840544/drug-label-0004-of-0014.json.zip
Source manifest SHA-256: cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run: 20260929T050834Z
Imported at: 2026-09-29 05:24:08

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 11 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application number		M017	openfda.application_number
brand name		Capsadyn	openfda.brand_name
generic name		CAPSAICIN	openfda.generic_name
manufacturer name		Chorda Pharma, Inc	openfda.manufacturer_name
ndc	package	83009-169-01	openfda.package_ndc
ndc	product	83009-169	openfda.product_ndc
ndc11	package	83009016901	derived:openfda.package_ndc
rxcui		199078	openfda.rxcui
spl id		07731045-0d2c-76b7-e063-6294a90af921	id
spl set id		07731045-0d2b-76b7-e063-6294a90af921	set_id
unii		S07O44R1ZM	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

For external use only. Do not apply to wounds and damaged skin. When using this produc t use only as directed, temporary warming of skin may be experienced after application, avoid contact with eyes or mucous membranes, do not bandage tightly, do not expose the treated area to heat, and avoid activity that may cause perspiration. Stop use and ask a doctor if condition worsens or if symptoms persist for more than 7 days or clear up and occur again within a few days.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.